<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article13</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/OAT" style="display:block; margin-bottom:10px;">OAT Original</a></li>
<h2><strong>OAT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Percutaneous Coronary Intervention in Stable Patients with Occluded Infarct-Related Artery". The New England Journal of Medicine. 2006.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In stable, high-risk patients with persistent total occlusion of the infarct-related coronary artery identified days after myocardial infarction, does percutaneous coronary intervention (PCI) in addition to optimal medical therapy reduce the risk of subsequent events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In stable patients with occluded infarct-related artery days after myocardial infarction, PCI did not reduce the occurrence of death, reinfarction, or heart failure compared to optimal medical therapy alone.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines do not recommend routine PCI for stable patients with occluded infarct-related artery beyond the period of expected myocardial salvage.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Randomized, controlled trial with 2166 stable patients enrolled between February 2000 and December 2005. Participants were divided into two groups: 1082 assigned to routine PCI plus optimal medical therapy and 1084 to optimal medical therapy alone.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Total occlusion of infarct-related artery identified 3 to 28 days after myocardial infarction<br/>
- Ejection fraction &lt;50% or proximal occlusion<br/>
<br/>
Exclusion Criteria:<br/>
- NYHA class III or IV heart failure, shock, serum creatinine &gt;2.5 mg/dL, significant left main or three-vessel coronary artery disease, rest angina, severe ischemia on stress testing<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Participants received either PCI with stenting and optimal medical therapy or optimal medical therapy alone.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes:<br/>
- Composite of death, myocardial reinfarction, or NYHA class IV heart failure<br/>
- 4-year cumulative primary event rate was 17.2% (PCI group) and 15.6% (medical therapy group), not statistically significant<br/>
<br/>
Secondary Outcomes:<br/>
- Similar rates of nonfatal reinfarction and NYHA class IV heart failure in both groups<br/>
- No interaction observed between treatment effect and any subgroup variable<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Trend towards excess nonfatal reinfarctions in the PCI group raised concerns<br/>
- Studies reflecting current PCI practice and use of drug-eluting stents were not performed<br/>
- Limitations in the data on thienopyridine use and long-term impact on left ventricular remodeling<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Grants from the National Heart, Lung, and Blood Institute (NHLBI) and various in-kind and monetary support from the pharmaceutical and medical device industry.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
ClinicalTrials.gov number NCT00004562. Additional results can be read in the full text of the study available at www.nejm.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
